Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

BACKGROUND: YN968D1 (Apatinib) selectively inhibits phosphorylation of VEGFR-2 and tumor angiogenesis in mice model. The study was conducted to determine the maximum tolerated dose (MTD), safety profile, pharmacokinetic variables, and antitumor activity in advanced solid malignancies. METHODS: This...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jin, Zhao, Xinmin, Chen, Lei, Guo, Haiyi, Lv, Fangfang, Jia, Ka, Yv, Ke, Wang, Fengqing, Li, Chuan, Qian, Jun, Zheng, Chunlei, Zuo, Yunxia
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2984425/
https://www.ncbi.nlm.nih.gov/pubmed/20923544
http://dx.doi.org/10.1186/1471-2407-10-529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2984425/
https://www.ncbi.nlm.nih.gov/pubmed/20923544
http://dx.doi.org/10.1186/1471-2407-10-529

Ejemplares similares